辉瑞是优于其他AI生物科技股的长期投资选择，因其估值更低、股息率高，且AI驱动的管线多元化成功。

On the other hand though, stock number two on our list um actually carries a much cheaper valuation, a mouthwatering dividend yield, and in my opinion is just the overall kind of better package to invest in long term. And that's going to be in the uh big pharma giants Fizer, ticker symbol PF, who most investors have completely written off after the pandemic highs where the pepperoni provided so much growth for them that they almost instantly became the largest biotech in the entire world.

But since then, once demand for those drugs plummeted, Fizer's financials corrected back down, causing the stock to crash by over half its entire value. Three things on that now. Number one, Fizer's stock price is now sitting even lower today than it did before the pandemic ever even happened. In fact, it's even lower than it was an entire decade ago. Yet, their financials are much higher than they ever were back then, which makes absolutely zero sense.

Number two, they made so much money from the pandemic that they went on arguably the largest acquisition sprees in pharma history. Certainly the biggest that I've ever seen, spending around $80 billion in total.

And number three, even if we put all of this aside, oh, back to the topic of this video, Fizer is diversifying well away from just pandemic era drugs. And a huge part of that is really being driven now by AI.

For example, they partnered with AWS to build what is known as the Fizer Scientific Data Cloud or SDC that basically compiles decades of historical molecule data, allowing their AI algorithms to instantly search and analyze all of it to design better drugs much faster than ever before across the entire pipeline.

On top of that, they just signed a big licensing deal to use a specialized biologics AI platform called Chi3, which they're now using to design brand new antibodies completely from scratch, predict molecule uh interactions much faster than ever before, too.

And they're even using machine learning to instantly match patients to clinical trials and optimize their regulatory submissions which all perfectly ties into their giant $43 billion acquisition of CGEN where Fiser is now combining this you know AI molecular design with antibbody drug conjugates what are known as ADCs.

These are basically guided kind of target missile therapies for cancer that can deliver chemotherapy directly to the the uh the tumor cells while avoiding healthy tissue. That could be a real gamecher for for one of the biggest diseases of course tragically in the world.

And when you look at their latest earnings report, well, you can actually see the early signs of this turnaround kind of gaining traction for them as their newly launched and acquired product sales actually soared by a huge 18% year-over-year. While just acquired products alone skyrocketed by even more, a bigger uh 25% growth.

Now, guys, this right here is exactly what I've been telling you that I kind of predicted would happen. I've been saying this for the past few years that as the stock was crashing into the ground, I warned you that this company already made all the profit that they were they would ever need from the pandemic years.

You know, regardless of of of what you know, our personal opinions or feelings are about the whole pandemic and and and the medications for it and all that kind of stuff. The the fact is just looking at this from an investment perspective alone, Fizer made unbelievable amounts of money from that. And so they already collected it and then they used it to acquire all of these new companies that are slowly going to be making up for the falling sales coming off the pandemic and a and eventually it's going to overtake that.

In fact, most people don't even know this, but Fizer has actually exceeded expectations on both the top and bottom line for almost every single quarter of the past 2 and 1/2 years already. And yet because of all the the the fear from investors, you know, coming off the pandemic, the the the crashing demand for for their um drugs and treatments, the stock is now insanely cheap. I mean, it's trading even lower than the sector by over 50% on a forward PE basis.

And the dividend has skyrocketed to one of its highest yields ever at above 6%. Which, you know, most of the time investors would be more than happy to just collect around half that amount. And it's also a pretty safe dividend, too, by the way. Um cuz Fiser has actually been implementing tons of cost cutting initiatives and this results in a pretty good payout ratio for them of less than 60%. With now over a decade and a half of consecutive growth on that dividend.

That's why I've been buying the stock myself and to this day I still think that it's probably one of the most slept on plays in the market for the long term. Again, just from an investment perspective alone, I know it's a controversial stock, but just from investing, like if you're putting your money somewhere, you know, hoping to get a return on it, I think Fizer, I don't know. To me, it's always looked like a like a pretty good deal coming off the pandemic off that giant crash.